NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal

Loxapine inhalation for the treatment of acute agitation with schizophrenia or bipolar disorder

Provisional matrix of consultees and commentators (pre-referral)

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Alexza Pharmaceuticals (loxapine inhalation)	 Board of Community Health Councils in Wales British National Formulary
Patient/carer groups	Care Quality Commission
Afiya Trust	Commissioning Support Appraisals
Black Health Agency	Service
Changes	Department of Health, Social Services
Chinese Mental Health Association	and Public Safety for Northern Ireland
Chinese National Healthy Living	Hafal
Centre	Medicines and Healthcare products
Counsel and Care	Regulatory Agency
Diverse Minds Saudities National Council	MIND Cymru
Equalities National Council	National Association of Primary Care
 Making Space Matthew Trust 	 National Mental Health Development Unit
 Max Appeal 	National Pharmacy Association
 Mental Health Foundation 	NHS Alliance
Mental Health Matters	NHS Commercial Medicines Unit
Mental Health Providers Forum	NHS Confederation
MDF The Bipolar Organisation	NHS Quality Improvement Scotland
MIND	Public Health Wales NHS Trust
Muslim Council of Britain	Scottish Medicines Consortium
Muslim Health Network	
National Perceptions Forum	Possible comparator manufacturers
Rethink	Actavis UK (risperidone)
SANE	 Dexcel Pharma (risperidone)
South Asian Health Foundation	Eli Lilly (olanzapine)
Specialised Healthcare Alliance	Genus Pharmaceuticals (lorazepam)
Together	Goldshield Pharmaceuticals
UK Advocacy Network	(haloperidol)
United Response	Janssen (haloperidol, risperidone)
• WISH – A voice for women's mental	 Pfizer (lorazepam, risperidone) Rosemont Pharmaceuticals
health	 Rosemont Pharmaceuticals (haloperidol)

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of loxapine inhalation for the treatment of acute agitation with schizophrenia or bipolar disorder

Consultees	Commentators (no right to submit or appeal)
 Professional groups British Association for Counselling and Psychotherapy British Association for Psychopharmacology British Association of Services to the Elderly British Association of Behavioural and Cognitive Psychotherapies British Association of Psychotherapists British Confederation of Psychotherapists British Geriatrics Society British Neuropsychiatry Association British Psychological Society College of Mental Health Pharmacy Counsellors and Psychotherapists in Primary Care Mental Health Nurses Association Primary Care Mental Health Education Royal College of Nursing Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal Society of Medicine United Kingdom Clinical Pharmacy Association United Kingdom Council for Psychotherapy Others Aneurin Bevan Health Board Department of Health NHS Tower Hamlets Welsh Assembly Government 	 Sandoz (risperidone) <u>Relevant research groups</u> Cochrane Depression, Anxiety & Neurosis Group Cochrane Schizophrenia Group Institute of Psychiatry MRC Clinical Trials Unit National Institute for Health Research National Primary Care Research & Development Centre Policy Research Institute on Ageing and Ethnicity Research Institute for the Care of Older People Evidence Review Group Evidence Review Group tbc National Institute for Health Research Health Technology Assessment Programme Associated Guideline groups National Collaborating Centre for Mental Health Associated Public Health groups Tbc

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.